Market Overview

HIV Drugs Market is projected to achieve a value of USD 23,370 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 32,140 Million by 2033 with a CAGR of 3.90% during the forecast period 2023-2033.

Human Immunodeficiency Virus Drugs are related with the treatment of HIV. Human Immunodeficiency Virus (HIV) is a virus that responsible for the condition known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency Virus (HIV) is the infection of virus which attacks the body’s immune system which helps to fight against the infection, specifically the CD4 cells also called as T cells, which help to fight against infections in the body.

Human Immunodeficiency Virus Drugs which assist to stop the multiplication of Human Immunodeficiency Virus, helps to decrease further complications. HIV Drugs markets growth attributed by various factors such as rising HIV patients particularly among youth, unprotected sexual contacts, uses of contaminated or nonsterile syringes to healthy people, lack of understanding about the risk factor.   

For instance, HIV is a major and progressive global public health issue, having recorded 40.4 million lives globally, with an estimated 38.4 million people living with the condition at the end of 2021, according to the WHO (World Health Organization).

Moreover, there is no any permeant treatment option to cure HIV.  Therapeutic treatment which available for this disease enable to increase the lifespan of patient, increase the quality of life and control the progression of disease. In recent years Advancements in Antiretroviral Therapy (ART) have transform the treatment of HIV. The development of combination therapies and Highly Active Antiretroviral Therapy (HAART)have significantly improved patient conditions.

COVID 19 pandemic significantly Impacts on the growth of HIV Drugs market due to worldwide lockdown cause disturbance in Import and export drug supply, focusing towards the COVID 19 testing rather than other diseases.  Because of that reduce new patient enrollment due to lack of diagnostic test. Thus, COVID-19 makes a negative impact on the growth of market.

Market Scope

 Market Dynamics

The HIV Drugs Market is driven by increasing prevalence of HIV patients, factor responsible for increasing prevalence includes lack of awareness of mode of transmission of virus, rise in treatment and diagnosis rate. Moreover, there is a huge escalation of government initiatives to increase awareness about HIV causes, available treatment options, symptoms of diseases.

HIV patients are treated as curing the illness and increasing the quality of life. As such permanent solution is not available yet to cure the HIV and save patient life. A wider use of pre-exposure prophylaxis(PrEP) which is a preventive approach to people who having a high risk of HIV. Pre-exposure prophylaxis(PrEP) is a drug which acts as a catalyst helps the body to produce antibodies, which help to fight against diseases causing germs and viruses.

Increasing the importance of R&D activities and government funding foe research in the field of Human Immunodeficiency Virus Drugs anticipates the growth of the market. Moreover, technological advancement enhances the delivery and long lasting effect of the drugs in HIV. For instance, according to the article March 2020, published by the National Institutes of Health (NIH), long-acting injectable nanoformulations of cabotegravir and rilpivirine used for HIV therapy were in phase III clinical trials. Cabotegravir was in advanced clinical development for HIV pre-exposure prophylaxis, and these formulations are expected to give results equivalent to traditional medicines, thus boosting the growth of HIV drugs market.

Furthermore, the increasing cost of advance therapeutic treatment and devices hamper the growth of the market. For overcome this problems government initiatives helps HIV patients in treatement. For Instance, Indian government run National AIDS control Organization which is a central funded organization to helps HIV patients. 

Overall, with the help of existing and combination treatment therapy the HIV Drugs Market is expected to witness significant growth in the coming years, driven by the introduction of new therapies and an increasing demand for effective treatments. Additionally, there is a need for advance and effective research and development to address the unmet needs of cancer treatment and to develop safe and effective therapies with lower side effects.

Market Drug Type Analysis

By Drug Type, the HIV Drugs Market is Categories into Protease Inhibitors, Fusion Inhibitors, CCR5 Antagonist, Nucleoside, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors. The T Nucleoside segment accounts for the largest share of around 42% of the Market in 2022.

The Nucleoside Therapy segment dominates the market because the therapeutic improving outcomes of this segment is greater than the other segments in the treatment of HIV and co-infection.

Market End-User Analysis

By End-user, the HIV Drugs Market is Categories into Hospitals & Clinics, Specialty Centers. The Hospital & Clinics segment accounts for the largest share of around 54% of the Market in 2022.

Rising investment in healthcare and increasing hospital facility in developed and developing market are major factor to drive the segment. Moreover, Hospitals are the primary healthcare facility where patient come for treatment. Also hospital having the infrastructure to diagnosis and identified the HIV or co-infection and advance treatment option.

Market Regional Analysis

North America dominate the HIV Drugs Market with the highest revenue generating market with share of more than 43%. The North America dominate this market due to the rising prevalence of HIV in US, easy availability of medications, new products launch. Additionally, strong presence of market player, well developed infra structure, higher number of research favor growth of region.

Europe having the second-largest market share in Market due to the rising demand for targeted medication, focus on R&D on HIV Drugs found in Europe. Moreover, government policies and increasing the elder population in the region significantly contribute to expand the market.

Asia-Pacific is estimated the fastest growing CAGR in HIV Drugs Market in forecasted period. This is due to increasing in healthcare expenditure and the rise in research and development activities in the pharmaceutical sector.

Competitive Analysis

The HIV Drugs Market is dominated by a few large companies, such as Boehringer Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co.,Ltd, ViiV Healthcare

There Are Some Of The Recent Developments Of The HIV Drugs Market:

July 2021 To make darunavir paired with ritonavir (DRV/r) as a second-line medication for HIV patients living in low and medium-income countries, Unitaid and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210 per patient per year.

March 2021 An agreement for collaboration to co-develop and co-commercialize long-acting HIV medication was made public by Gilead Sciences Inc. and Merck. To create a two-drug HIV treatment regimen, the firms want to combine lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor from Merck.

In Aug 2018, Merck & Co., Inc. announced that FDA approved its two new antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of HIV-1, the most common strain of virus.

By Drug Type

·         Protease Inhibitors

·         Fusion Inhibitors

·         CCR5 Antagonist

·         Nucleosidz

·         Integrase Inhibitors

·         Non-Nucleoside Reverse Transcriptase Inhibitors

·  

By End-User

·         Hospitals & Clinics

·         Specialty Centers